Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Estrogen Receptor Positive 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Vorinostat 2Stem Cell Transplantation 2Rituximab 2Gemcitabine 2Busulfan 2Brentuximab Vedotin 2romidepsin 1pembrolizumab 1molibresib 1entinostat 1copanlisib 1belinostat 1Tacrolimus 1Pyridoxine 1Panobinostat 1Mycophenolic Acid 1Melphalan 1Health Resources 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Filgrastim 1Fibroblast Growth Factor 7 1Dexamethasone 1Cyclophosphamide 1Cryotherapy 1Clofarabine 1Calcium Dobesilate 1CT-P10 1Bortezomib 1BI 6727 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, T-Cell × copanlisib × Clear all
NCT04233697 2020-08-13

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Columbia University

Phase 1 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡